<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32146727</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1369-1600</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Addiction biology</Title>
          <ISOAbbreviation>Addict Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side.</ArticleTitle>
        <Pagination>
          <StartPage>e12892</StartPage>
          <MedlinePgn>e12892</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/adb.12892</ELocationID>
        <Abstract>
          <AbstractText>For several decades, studies conducted to evaluate the efficacy of RS(±)-Baclofen in the treatment of alcohol dependence yielded contrasting results. Human and animal studies recently questioned the use of the racemic drug in patients since a potential important role of the different enantiomers has been revealed with an efficacy thought to reside with the active R(+)-enantiomer. Here we conducted experiments in the postdependent rat model of alcohol dependence to compare the efficacy of R(+)-Baclofen or S(-)-Baclofen to that of RS(±)-Baclofen on ethanol intake, seeking, and relapse. R(+)-Baclofen was more effective than RS(±)-Baclofen in reducing ethanol intake and seeking during acute withdrawal and during relapse after abstinence. We also used an original population approach in order to identify drug responders. We found a significant proportion of responders to S(-)-Baclofen and RS(±)-Baclofen, displaying an increase in ethanol intake, and this increasing effect on alcohol intake was not seen in the R(+)-Baclofen group. At an intermediate dose of R(+)-Baclofen, devoid of any motor side effects, we identified a very large proportion of responders (75%) with a large decrease in ethanol intake (90% decrease). Finally, the response to RS(±)-Baclofen on ethanol intake was correlated to plasma level of Baclofen. R(+)-Baclofen and RS(±)-Baclofen were effective in reducing sucrose intake. Our study has important clinical implication since it suggests that the wide variability in the therapeutic responses of patients to RS(±)-Baclofen may come from the sensitivity to the R(+)-Baclofen but also to the one of the S(-)-Baclofen that can promote an increase in ethanol intake.</AbstractText>
          <CopyrightInformation>© 2020 Society for the Study of Addiction.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Echeverry-Alzate</LastName>
            <ForeName>Victor</ForeName>
            <Initials>V</Initials>
            <Identifier Source="ORCID">0000-0001-9059-3513</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR 1247-Research Group on Alcohol and Pharmacodependences (GRAP), Université de Picardie Jules Verne, Amiens, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Psychobiology &amp; Behavioral Sciences Methods, School of Psychology, Complutense University of Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jeanblanc</LastName>
            <ForeName>Jérôme</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-0353-2777</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR 1247-Research Group on Alcohol and Pharmacodependences (GRAP), Université de Picardie Jules Verne, Amiens, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sauton</LastName>
            <ForeName>Pierre</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM UMR 1247-Research Group on Alcohol and Pharmacodependences (GRAP), Université de Picardie Jules Verne, Amiens, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bloch</LastName>
            <ForeName>Vanessa</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>INSERM UMR-S 1144, Université de Paris, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculté de Médecine, Université de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Labat</LastName>
            <ForeName>Laurence</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0001-8291-3054</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR-S 1144, Université de Paris, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculté de Médecine, Université de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soichot</LastName>
            <ForeName>Marion</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratoire de Toxicologie Biologique - Hôpital Lariboisière, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vorspan</LastName>
            <ForeName>Florence</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-5168-3727</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR-S 1144, Université de Paris, Optimisation Thérapeutique en Neuropsychopharmacologie, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculté de Médecine, Université de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Département de Psychiatrie et de Médecine Addictologique, Hôpital Fernand Widal, Assistance Publique - Hôpitaux de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Naassila</LastName>
            <ForeName>Mickael</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-9788-0918</Identifier>
            <AffiliationInfo>
              <Affiliation>INSERM UMR 1247-Research Group on Alcohol and Pharmacodependences (GRAP), Université de Picardie Jules Verne, Amiens, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>03</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Addict Biol</MedlineTA>
        <NlmUniqueID>9604935</NlmUniqueID>
        <ISSNLinking>1355-6215</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058786">GABA-B Receptor Agonists</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H789N3FKE8</RegistryNumber>
          <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058786" MajorTopicYN="N">GABA-B Receptor Agonists</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">GABAB receptor</Keyword>
        <Keyword MajorTopicYN="Y">R(+)-Baclofen</Keyword>
        <Keyword MajorTopicYN="Y">RS(±)-Baclofen</Keyword>
        <Keyword MajorTopicYN="Y">S(−)-Baclofen</Keyword>
        <Keyword MajorTopicYN="Y">alcohol use disorder</Keyword>
        <Keyword MajorTopicYN="Y">operant oral alcohol self-administration</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>7</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>18</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32146727</ArticleId>
        <ArticleId IdType="doi">10.1111/adb.12892</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Rehm J, Anderson P, Barry J, et al. Prevalence of and potential influencing factors for alcohol dependence in Europe. Eur Addict Res. 2015;21(1):6-18.</Citation>
        </Reference>
        <Reference>
          <Citation>Paille F, Reynaud M. L'alcool, une des toutes premières causes d'hospitalisation en France. BEH. 2015;440-449.</Citation>
        </Reference>
        <Reference>
          <Citation>Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-866.</Citation>
        </Reference>
        <Reference>
          <Citation>Jonas DE, Amick HR, Feltner C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings. JAMA. 2014;311(18):1889-1900.</Citation>
        </Reference>
        <Reference>
          <Citation>Logge WB, Morris RW, Baillie AJ, Haber PS, Morley KC. Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berl). 2019. https://doi.org/10.1007/s00213-019-05192-5</Citation>
        </Reference>
        <Reference>
          <Citation>de Beaurepaire R, Benyamina A, Granger B, Hill C, Sicard D, Jaury P. Sécurité du baclofène: l'étrange appréciation de l'Agence française du médicament. PSN. 2018;16:37-53.</Citation>
        </Reference>
        <Reference>
          <Citation>Rose AK, Jones A. Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta-analysis. Addiction. 2018;113(8):1396-1406.</Citation>
        </Reference>
        <Reference>
          <Citation>Minozzi S, Saulle R, Rösner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018;11:CD012557. https://doi.org/10.1002/14651858.CD012557.pub2</Citation>
        </Reference>
        <Reference>
          <Citation>Rolland B, Labreuche J, Duhamel A, et al. Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol. 2015;25(10):1631-1636.</Citation>
        </Reference>
        <Reference>
          <Citation>Rolland B, Paille F, Fleury B, Cottencin O, Benyamina A, Aubin H-J. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey. PLoS One. 2014;9(6):e98062. https://doi.org/10.1371/journal.pone.0098062</Citation>
        </Reference>
        <Reference>
          <Citation>Agabio R, Sinclair JM, Addolorato G, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 2018;5(12):957-960.</Citation>
        </Reference>
        <Reference>
          <Citation>Morley KC, Baillie A, Leung S, Addolorato G, Leggio L, Haber PS. Baclofen for the treatment of alcohol dependence and possible role of comorbid anxiety. Alcohol Alcohol. 2014;49(6):654-660.</Citation>
        </Reference>
        <Reference>
          <Citation>Marsot A, Imbert B, Alvarez J-C, et al. High variability in the exposure of baclofen in alcohol-dependent patients. Alcohol Clin Exp Res. 2014;38(2):316-321.</Citation>
        </Reference>
        <Reference>
          <Citation>Durant CF, Paterson LM, Turton S, et al. Using Baclofen to explore GABA-B receptor function in alcohol dependence: insights from pharmacokinetic and pharmacodynamic measures. Front Psych. 2018;9:664. https://doi.org/10.3389/fpsyt.2018.00664</Citation>
        </Reference>
        <Reference>
          <Citation>Farokhnia M, Deschaine SL, Sadighi A, et al. A deeper insight into how GABA-B receptor agonism via baclofen may affect alcohol seeking and consumption: lessons learned from a human laboratory investigation. Mol Psychiatry. 2018;31. https://doi.org/10.1038/s41380-018-0287-y</Citation>
        </Reference>
        <Reference>
          <Citation>Simon N, Franchitto N, Rolland B. Pharmacokinetic studies of Baclofen are not sufficient to establish an optimized dosage for management of alcohol disorder. Front Psych. 2018;9:485.</Citation>
        </Reference>
        <Reference>
          <Citation>Chevillard L, Sabo N, Tod M, et al. Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. Fundam Clin Pharmacol. 2018;32(2):239-248.</Citation>
        </Reference>
        <Reference>
          <Citation>Daoust M, Saligaut C, Lhuintre JP, Moore N, Flipo JL, Boismare F. GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol. 1987;4:469-472.</Citation>
        </Reference>
        <Reference>
          <Citation>Anstrom KK, Cromwell HC, Markowski T, Woodward DJ. Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res. 2003;27:900-908.</Citation>
        </Reference>
        <Reference>
          <Citation>Stromberg MF. The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol Biochem Behav. 2004;78:743-750.</Citation>
        </Reference>
        <Reference>
          <Citation>Janak PH, Michael GT. Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose. Alcohol. 2003;30(1):1-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombo G, Agabio R, Carai MAM, et al. Ability of Baclofen in reducing alcohol intake and withdrawal severity: I-Preclinical Evidence. Alcohol Clin Exp Res. 2000;24:58-66.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombo G, Serra S, Vacca G, Carai MAM, Gessa GL. Effect of the combination of naltrexone and baclofen, on acquisition of alcohol drinking behavior in alcohol-preferring rats. Drug Alcohol Depend. 2005;77(1):87-91.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith BR, Boyle AE, Amit Z. The effects of the GABA(B) agonist baclofen on the temporal and structural characteristics of ethanol intake. Alcohol. 1999;17(3):231-240.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith BR, Robidoux J, Amit Z. GABAergic involvement in the acquisition of voluntary ethanol intake in laboratory rats. Alcohol Alcohol. 1992;27(3):227-231.</Citation>
        </Reference>
        <Reference>
          <Citation>Petry NM. Benzodiazepine-GABA modulation of concurrent ethanol and sucrose reinforcement in the rat. Exp Clin Psychopharmacol. 1997;5(3):183-194.</Citation>
        </Reference>
        <Reference>
          <Citation>Olpe H-R, Demiéville H, Baltzer V, et al. The biological activity of d-baclofen (Lipresal®). Eur J Pharmacol. 1978;52(1):133-136.</Citation>
        </Reference>
        <Reference>
          <Citation>Jeanblanc J, Sauton P, Jeanblanc V, et al. Face validity of a pre-clinical model of operant binge drinking: just a question of speed. Addict Biol. 2018;23:643-652.</Citation>
        </Reference>
        <Reference>
          <Citation>González-Marín MC, Lebourgeois S, Jeanblanc J, Diouf M, Naassila M. Evaluation of alcohol use disorders pharmacotherapies in a new preclinical model of binge drinking. Neuropharmacology. 2018;140:14-24.</Citation>
        </Reference>
        <Reference>
          <Citation>Jeanblanc J, Rolland B, Gierski F, Martinetti MP, Naassila M. Animal models of binge drinking, current challenges to improve face validity. Neurosci Biobehav Rev. 2019;106:112-121.</Citation>
        </Reference>
        <Reference>
          <Citation>Meinhardt MW, Sommer WH. Postdependent state in rats as a model for medication development in alcoholism. Addict Biol. 2015;20(1):1-21.</Citation>
        </Reference>
        <Reference>
          <Citation>Barbier E, Johnstone AL, Khomtchouk BB, et al. Dependence-induced increase of alcohol self-administration and compulsive drinking mediated by the histone methyltransferase PRDM2. Mol Psychiatry. 2017;22(12):1746-1758.</Citation>
        </Reference>
        <Reference>
          <Citation>Reynaud M, Aubin H-J, Trinquet F, et al. A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients-the ALPADIR study. Alcohol Alcohol. 2017;52(4):439-446.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombo G, Carai MAM, Gessa GL. Suppression by γ-Hydroxybutyric Acid of “Alcohol deprivation effect” in rats: preclinical evidence of its anti-relapse properties. Front Psych. 2012;3:95.</Citation>
        </Reference>
        <Reference>
          <Citation>Colombo G, Vacca G, Serra S, Brunetti G, Carai MAM, Gessa GL. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (Berl). 2003;167(3):221-224.</Citation>
        </Reference>
        <Reference>
          <Citation>Lorrai I, Maccioni P, Gessa GL, Colombo G. R(+)-Baclofen, but not S(−)-Baclofen, alters alcohol self-administration in alcohol-preferring rats. Front Psych. 2016;7(68).</Citation>
        </Reference>
        <Reference>
          <Citation>Walker BM, Koob GF. The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. 2007;31(1):11-18.</Citation>
        </Reference>
        <Reference>
          <Citation>Fattore L. Baclofen antagonizes intravenous self-administration of nicotine in mice and rats. Alcohol Alcohol. 2002;37(5):495-498.</Citation>
        </Reference>
        <Reference>
          <Citation>Wise RA. Voluntary ethanol intake in rats following exposure to ethanol on various schedules. Psychopharmacologia. 1973;29(3):203-210.</Citation>
        </Reference>
        <Reference>
          <Citation>Simms JA, Steensland P, Medina B, et al. Intermittent Access to 20% Ethanol Induces High Ethanol Consumption in Long-Evans and Wistar Rats. Alcohol Clin Exp Res. 2008;32(10):1816-1823.</Citation>
        </Reference>
        <Reference>
          <Citation>Simon O'Brien E, Legastelois R, Houchi H, et al. Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. Neuropsychopharmacology. 2011;36(7):1518-1530.</Citation>
        </Reference>
        <Reference>
          <Citation>Alaux-Cantin S, Warnault V, Legastelois R, et al. Alcohol intoxications during adolescence increase motivation for alcohol in adult rats and induce neuroadaptations in the nucleus accumbens. Neuropharmacology. 2013;67:521-531.</Citation>
        </Reference>
        <Reference>
          <Citation>Simon-O'Brien E, Alaux-Cantin S, Warnault V, Buttolo R, Naassila M, Vilpoux C. The histone deacetylase inhibitor sodium butyrate decreases excessive ethanol intake in dependent animals. Addict Biol. 2015;20(4):676-689.</Citation>
        </Reference>
        <Reference>
          <Citation>Alaux-Cantin S, Buttolo R, Houchi H, Jeanblanc J, Naassila M. Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. Addict Biol. 2015;20(5):890-901.</Citation>
        </Reference>
        <Reference>
          <Citation>Houchi H, Persyn W, Legastelois R, Naassila M. The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals. Addict Biol. 2013;18:812-825.</Citation>
        </Reference>
        <Reference>
          <Citation>Lebourgeois S, Vilpoux C, Jeanblanc J, et al. Pharmacological activation of mGlu4 and mGlu7 receptors, by LSP2-9166, reduces ethanol consumption and relapse in rat. Neuropharmacology. 2018;133:163-170.</Citation>
        </Reference>
        <Reference>
          <Citation>Lebourgeois S, González-Marín MC, Jeanblanc J, Naassila M, Vilpoux C. Effect of N -acetylcysteine on motivation, seeking and relapse to ethanol self-administration. Addict Biol. 2018;23(2):643-652.</Citation>
        </Reference>
        <Reference>
          <Citation>Jeanblanc J, Balguerie K, Coune F, Legastelois R, Jeanblanc V, Naassila M. Light alcohol intake during adolescence induces alcohol addiction in a neurodevelopmental model of schizophrenia. Addict Biol. 2015;20(3):490-499.</Citation>
        </Reference>
        <Reference>
          <Citation>Labat L, Goncalves A, Cleophax C, Megarbane B, Decleves X. Dosage du baclofène dans le plasma en chromatographie phase liquide couplée à de la spectrométrie de masse en tandem: à propos d'un cas de surdosage. Toxicol Anal Clin. 2016;28:211-217.</Citation>
        </Reference>
        <Reference>
          <Citation>Agabio R, Leggio L. Baclofen in the treatment of patients with alcohol use disorder and other mental health disorders. Front Psych. 2018;9:464.</Citation>
        </Reference>
        <Reference>
          <Citation>Kasten CR, Blasingame SN, Boehm SL. Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption. Alcohol. 2015;49(1):37-46.</Citation>
        </Reference>
        <Reference>
          <Citation>Kasten CR, Boehm SL. Intra-nucleus accumbens shell injections of R(+)- and S(−)-baclofen bidirectionally alter binge-like ethanol, but not saccharin, intake in C57Bl/6J mice. Behav Brain Res. 2014;272:238-247.</Citation>
        </Reference>
        <Reference>
          <Citation>Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: a preliminary open-label study. Alcohol Clin Exp Res. 2004;28(10):1517-1523.</Citation>
        </Reference>
        <Reference>
          <Citation>Rolland B, Paille F, Mann K, Aubin H-J. The 2015 French guidelines on alcohol misuse, issued in partnership with the European Federation of Addiction Societies: a focus on children and adolescents. Eur Child Adolesc Psychiatry. 2016;25:1145-1148.</Citation>
        </Reference>
        <Reference>
          <Citation>Leggio L, Garbutt J, Addolorato G. Effectiveness and safety of Baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9:33-44.</Citation>
        </Reference>
        <Reference>
          <Citation>Mann K, Torup L, Sørensen P, et al. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. Eur Neuropsychopharmacol. 2016;26(12):1941-1949.</Citation>
        </Reference>
        <Reference>
          <Citation>Grüsser SM, Wrase J, Klein S, et al. Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl). 2004;175(3):296-302.</Citation>
        </Reference>
        <Reference>
          <Citation>Imbert B, Alvarez J-C, Simon N. Anticraving effect of Baclofen in alcohol-dependent patients. Alcohol Clin Exp Res. 2015;39(9):1602-1608.</Citation>
        </Reference>
        <Reference>
          <Citation>Maccioni P, Pes D, Fantini N, Carai MAM, Gessa GL, Colombo G. $γ$-Hydroxybutyric acid (GHB) suppresses alcohol's motivational properties in alcohol-preferring rats. Alcohol. 2008;42(2):107-113.</Citation>
        </Reference>
        <Reference>
          <Citation>Vengeliene V, Takahashi TT, Dravolina OA, et al. Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. Psychopharmacology (Berl). 2018;235(7):1955-1965.</Citation>
        </Reference>
        <Reference>
          <Citation>Czachowski CL, Legg BH, Stansfield KH. Ethanol and sucrose seeking and consumption following repeated administration of the GABA(B) agonist baclofen in rats. Alcohol Clin Exp Res. 2006;30:812-818.</Citation>
        </Reference>
        <Reference>
          <Citation>Falch E, Hedegaard A, Nielsen L, Jensen BR, Hjeds H, Krogsgaard-Larsen P. Comparative stereostructure-activity studies on GABAA and GABAB receptor sites and GABA uptake using rat brain membrane preparations. J Neurochem. 2006;47(3):898-903.</Citation>
        </Reference>
        <Reference>
          <Citation>Witczuk B, Khaunina RA, Kupryszewski G. 3-(p-Chlorophenyl)-4-aminobutanoic acid--resolution into enantiomers and pharmacological activity. Pol J Pharmacol Pharm. 1980;32:187-196.</Citation>
        </Reference>
        <Reference>
          <Citation>Fromm GH, Shibuya T, Nakata M, Terrence CF. Effects of d-baclofen and l-baclofen on the trigeminal nucleus. Neuropharmacology. 1990;29(3):249-254.</Citation>
        </Reference>
        <Reference>
          <Citation>Sanchez-Ponce R, Wang L-Q, Lu W, von Hehn J, Cherubini M, Rush R. Metabolic and pharmacokinetic differentiation of STX209 and racemic Baclofen in humans. Metabolites. 2012;2(3):596-613.</Citation>
        </Reference>
        <Reference>
          <Citation>Bowery NG, Hill DR, Hudson AL. Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes. Br J Pharmacol. 1983;78(1):191-206.</Citation>
        </Reference>
        <Reference>
          <Citation>Waddington JL, Cross AJ. Gaba-ergic properties of baclofen in vivo and in vitro. Brain Res Bull. 1980;5:503-505.</Citation>
        </Reference>
        <Reference>
          <Citation>Karbon EW, Duman RS, Enna SJ. GABAB receptors and norepinephrine-stimulated cAMP production in rat brain cortex. Brain Res. 1984;306(1-2):327-332.</Citation>
        </Reference>
        <Reference>
          <Citation>Aufrère G, Le Bourhis B, Beaugé F. Ethanol intake after chronic intoxication by inhalation of ethanol vapour in rats: behavioural dependence. Alcohol Published Online First. 1997;14(3):247-253.</Citation>
        </Reference>
        <Reference>
          <Citation>Priddy BM, Carmack SA, Thomas LC, Vendruscolo JCM, Koob GF, Vendruscolo LF. Sex, strain, and estrous cycle influences on alcohol drinking in rats. Pharmacol Biochem Behav. 2017;152:61-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Funk D, Coen K, Tamadon S, Lê AD. Effect of chronic alcohol vapor exposure on reinstatement of alcohol seeking induced by U50,488. Neuropharmacology. 2019;148:210-219.</Citation>
        </Reference>
        <Reference>
          <Citation>Bespalov A, Müller R, Relo AL, Hudzik T. Drug tolerance: a known unknown in translational neuroscience. Trends Pharmacol Sci. 2016;37(5):364-378.</Citation>
        </Reference>
        <Reference>
          <Citation>Lal R, Sukbuntherng J, Tai EHL, et al. Arbaclofen Placarbil, a novel R-Baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-Baclofen. J Pharmacol Exp Ther. 2009;330(3):911-921.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
